You would like to take part in this adventure? Here's a selection of a few success stories!
Biotechnology, precision medicine, radiotherapy, instrumentation... The fields of activity of start-ups that have emerged from Institut Curie are as varied as their applications and technologies.
Here is a selection of start-ups that have benefited from Institut Curie's incubation program.
Incubated at Institut Curie, One Biosciences was found in 2020, based on the work of its co-founder Céline Vallot, head of the Dynamics of Epigenetic Alterations in Cancer Team at Institut Curie. The start-up is specialized in leveraging the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. Full of ambition, One Biosciences plans to grow its team and strike research collaborations with clinical centers of excellence to build its pipeline of potential targets, in the field of oncology and beyond.
Céline Vallot, PhD, co-founder of One Biosciences & head of Institut Curie's Dynamics of Epigenetic Alterations in Cancer Team
Founded in 2018 by Institut Curie, Honing Biosciences is a bio-therapeutics company that develops and improves cell-based therapies, in particular for cancer and other chronic diseases. The start-up results from from the work of Institut Curie's Cell Biology and Cancer Team led by Franck Perez. Honing Biosciences was the first company in which Institut Curie had invested since the implementation of its new technology transfer policy in 2017, and the creation of a dedicated division to support the creation of start-ups resulting from the work of its teams. In 2020, the company announced a €2 million fund raising, obtained from the PSL Innovation Fund (Elaia), a private investor and BPI France.
Franck Perez, PhD, co-founder of Honing Biosciences & head of Institut Curie's Cell Biology and Cancer Team